What is MS Pharma?
MS Pharma operates as a multinational pharmaceutical entity with a specialized focus on the development, manufacturing, and distribution of essential medicines. Its market position is defined by a deep integration into the healthcare systems of the Middle East and Africa, where it serves as a primary provider of affordable therapeutic solutions. The company maintains a comprehensive portfolio that spans multiple therapeutic areas, supported by advanced research and development centers and regional manufacturing facilities. By prioritizing accessibility and quality, MS Pharma acts as a vital link in the regional healthcare value chain, facilitating improved patient outcomes through consistent pharmaceutical availability.
How much funding has MS Pharma raised?
MS Pharma has raised a total of $75M across 2 funding rounds:
Debt
$30M
Private Equity
$45M
Debt (2015): $30M with participation from European Bank for Reconstruction and Development
Private Equity (2017): $45M led by International Finance Corporation
Key Investors in MS Pharma
European Bank for Reconstruction and Development
The European Bank for Reconstruction and Development (EBRD) is a multilateral bank committed to the development of market-oriented economies and the promotion of the private and entrepreneurial initiatives.
International Finance Corporation
International Finance Corporation operates as a multilateral financial institution dedicated to mobilizing capital and expertise for sustainable development across emerging markets.
What's next for MS Pharma?
With the recent infusion of capital, MS Pharma is well-positioned to accelerate its strategic initiatives, particularly in the expansion of its specialty medicine portfolio and the modernization of its manufacturing footprint. The company is expected to focus on deepening its penetration in high-growth markets while enhancing its R&D capabilities to address evolving medical challenges. As it navigates the complexities of the regional healthcare sector, the firm will likely prioritize operational efficiency and strategic partnerships to maintain its competitive edge. The continued support from multilateral financial institutions suggests a long-term commitment to sustainable development and the strengthening of regional pharmaceutical infrastructure, setting the stage for further scaling of its core business operations.
See full MS Pharma company page
